LYOPHILIZED FORMULATION OF TAT-NR2B9C

(19)

(11)

EP 2 925 338 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	22.05.2019 Bulletin 2019/21

(45)	Mention of the grant of the patent:
	27.03.2019 Bulletin 2019/13

(21)	Application number: 13859059.1

(22)	Date of filing: 25.11.2013

(51)

International Patent Classification (IPC):

A61K 9/00^(2006.01)
A61K 38/08^(2019.01)
A61K 38/17^(2006.01)
A61K 47/26^(2006.01)

A61K 9/19^(2006.01)
A61K 38/10^(2006.01)
A61K 47/18^(2017.01)

(86)	International application number:
	PCT/US2013/071755

(87)	International publication number:
	WO 2014/085349 (05.06.2014 Gazette 2014/23)

(54)	LYOPHILIZED FORMULATION OF TAT-NR2B9C LYOPHILISIERTE FORMULIERUNG VON TAT-NR2B9C FORMULATION LYOPHILISÉE DE TAT-NR2B9C

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

28.11.2012 US 201261730952 P

(43)	Date of publication of application:
	07.10.2015 Bulletin 2015/41

(73)	Proprietor: NoNO Inc.
	Toronto, ON M8X 1R5 (CA)

(72)	Inventor:
	GARMAN, Jonathan David Thornhill, Ontario L4J 8N1 (CA)

(74)	Representative: Nederlandsch Octrooibureau
	P.O. Box 29720 2502 LS The Hague 2502 LS The Hague (NL)

(56)

References cited: :

WO-A2-2012/021854
US-A1- 2007 140 981
US-A1- 2012 252 731

US-A- 5 605 884
US-A1- 2010 082 985
US-B2- 7 060 268

CARPENTER J F ET AL: "RATIONAL DESIGN OF STABLE LYOPHILIZED PROTEIN FORMULATIONS: THEORY AND PRACTICE", PHARMACEUTICAL BIOTECHNOLOGY, KLUWER, DORDRECHT, NL, vol. 13, 1 January 2002 (2002-01-01), pages 109-133, XP009053337, ISSN: 1078-0467

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).